Relevant bibliographies by topics / Innocare

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Innocare'

Author: Grafiati
Published: 29 June 2021
Last updated: 29 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Innocare.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Innocare"

1

Zhou, Daobin, Jie Jin, Zheng-zheng Fu, et al. "Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients." Blood 138, Supplement 1 (2021): 46. http://dx.doi.org/10.1182/blood-2021-149350.

Full text
Abstract:
Abstract Background Waldenstrom's Macroglobulinemia (WM) is a B-cell disorder characterized primarily by bone marrow infiltration with lymphoplasmacytic cells, along with immunoglobulin M (IgM) monoclonal gammopathy. Bruton's tyrosine kinase (BTK) plays a key role in signaling pathways for the survival of WM clone, particular in patients harboring MYD88 L265P mutations. However, due to target selectivity issue, Clinical uses of early BTK inhibitors are still compromised with off-target activities to many other kinases besides BTK. Orelabrutinib is a novel, highly potent small molecule inhibito
APA, Harvard, Vancouver, ISO, and other styles
2

Xu, Wei, Yongping Song, Zengjun Li, et al. "Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia." Blood 134, Supplement_1 (2019): 4319. http://dx.doi.org/10.1182/blood-2019-123331.

Full text
Abstract:
Bruton's Tyrosine Kinase (BTK) plays a critical role in B-cell receptor (BCR) signaling, which mediates B-cell proliferation, migration, and adhesion. As a therapeutic target, its clinical significance has been well established in multiple subtypes of non-Hodgkin's lymphoma (NHL). Orelabrutinib (ICP-022) is a novel, potent irreversible BTK inhibitor with much improved target selectivity in comparison to Ibrutinib and Acalabrunitib, which leads to improved safety profiles. With a proprietary formulation, Orelabrutinib achieves high bioavailability comparing to other BTK inhibitors. Results of P
APA, Harvard, Vancouver, ISO, and other styles
3

Song, Yuqin, Yongping Song, Lihong Liu, et al. "Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study." Blood 134, Supplement_1 (2019): 755. http://dx.doi.org/10.1182/blood-2019-126305.

Full text
Abstract:
Mantle cell lymphoma (MCL), a subtype of aggressive B-cell non-Hodgkin lymphoma (NHL), remains challenging with unsatisfied outcomes from standard therapy. The clinical significance of Bruton's Tyrosine Kinase (BTK) inhibitors has been validated in multiple subtypes of NHL. Ibrutinib, the first BTK inhibitor, has been approved by FDA for the treatment of refractory and relapse (r/r) MCL. In spite of encouraging efficacy, clinically often referred adverse events such as diarrhea, bleeding and atrial fibrillation, respectively following ibrutinib treatment. It has been hypothesized that poor tar
APA, Harvard, Vancouver, ISO, and other styles
4

Xu, Wei, Yongping Song, Tingyu Wang, et al. "Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia." Blood 136, Supplement 1 (2020): 26–27. http://dx.doi.org/10.1182/blood-2020-134531.

Full text
Abstract:
Orelabrutinib (ICP-022) is a novel and highly selective irreversible BTK inhibitor. We previously reported that orelabrutinib had high bioavailability with ~100% BTK occupancy at 24 hours at 150 mg daily dosing regimen and demonstrated excellent safety and efficacy profiles at median follow-up of 8.7 months in a Phase I/II trial of refractory/relapsed (r/r) CLL/SLL (Chronic Lymphocytic Leukemia/Small Cell Leukemia). Here we present an updated analysis of efficacy and safety results from the clinical study of Orelabrutinib in Chinese patients with r/r CLL/SLL following extended treatment. This
APA, Harvard, Vancouver, ISO, and other styles
5

Li, R., X. Zhu, S. Liu, et al. "LB0005 ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE (BTK), FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IB/IIA DOSE-FINDING STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 210.2–210. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5086a.

Full text
Abstract:
BackgroundOrelabrutinib is an oral, highly-selective, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). Orelabrutinib has been approved for the treatment of B cell malignancies in China. Two distinct lupus animal models showed significant efficacy of orelabrutinib in reducing disease activity, which supported the clinical development of orelabrutinib in Systemic Lupus Erythematosus (SLE).ObjectivesThis phase Ib/IIa, randomized, double-blind, placebo-controlled, dose-finding study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), preliminary effic
APA, Harvard, Vancouver, ISO, and other styles
6

Song, Yuqin, Wei Xu, Yongping Song, et al. "Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies." Blood 136, Supplement 1 (2020): 43. http://dx.doi.org/10.1182/blood-2020-140172.

Full text
Abstract:
Background: Bruton tyrosine kinase (BTK) is one of the key kinases implicated in the pathogenesis of multiple B cell malignancies. Orelabrutinib is a novel, highly selective and potent irreversible BTK inhibitor with minimal activities against other kinases (ITK, EGFR, ERBB2, etc.). As thus orelabrutinib may avoid off-target related adverse events and shall have improved safety profiles comparing to other BTK inhibitors. Here we present the safety profile of orelabrutinib analyzed based on data from 5 ongoing clinical studies in B cell malignancies (Table 1). Methods: Safety data of 266 patien
APA, Harvard, Vancouver, ISO, and other styles
7

Song, Yuqin, Yongping Song, Lihong Liu, et al. "Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study." Blood 136, Supplement 1 (2020): 1. http://dx.doi.org/10.1182/blood-2020-141781.

Full text
Abstract:
Background: In spite of years of effort, Mantle Cell Lymphoma (MCL) remains a clinical challenge. The clinical significance of Bruton's Tyrosine Kinase (BTK) inhibitor has been validated with the approvals by FDA for the treatment of multiple subtypes of NHL including refractory and relapse (r/r) MCL. However, some serious adverse events (AEs) due to poor target selectivity (inhibition of EGFR, TEC, BMX and others), such as diarrhea, sever bleeding and atrial fibrillation, remain as challenges in clinic. Orelabrutinib is a novel, potent irreversible BTK inhibitor with high selectivity for BTK.
APA, Harvard, Vancouver, ISO, and other styles
8

Xu, Wei, Yongping Song, Tingyu Wang, et al. "Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study." Blood 138, Supplement 1 (2021): 2638. http://dx.doi.org/10.1182/blood-2021-146491.

Full text
Abstract:
Abstract Introduction Orelabrutinib is a novel and highly selective irreversible Bruton tyrosine kinase (BTK) inhibitor approved in China for the treatment of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We previously reported that orelabrutinib had high bioavailability with ~100% BTK occupancy at 24 hours at 150 mg daily dosing regimen and had demonstrated excellent safety and efficacy profiles in a phase II trial of R/R CLL/SLL. Here we present the long-term result of this study. Methods This is an open-label, multicenter, phase I
APA, Harvard, Vancouver, ISO, and other styles
9

Eyre, Toby A., Nirav N. Shah, Steven Le Gouill, et al. "BRUIN MCL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)." Blood 138, Supplement 1 (2021): 2422. http://dx.doi.org/10.1182/blood-2021-145920.

Full text
Abstract:
Abstract Background: Covalent Bruton's Tyrosine Kinase (BTK) inhibitors (BTKi) have transformed the management of relapsed mantle cell lymphoma (MCL), but these treatments are not curative and the majority of patients will require additional treatment. Covalent BTKi share pharmacologic liabilities (e.g. low oral bioavailability, short half-life) that collectively may lead to suboptimal BTK target coverage especially in rapidly proliferating tumors with high BTK protein turnover such as MCL. To address these limitations, pirtobrutinib, a highly selective, non-covalent BTKi that inhibits both wi
APA, Harvard, Vancouver, ISO, and other styles
10

Guo, Ye, Chunwang Yuan, Weimin Ding, et al. "Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study." Journal of Clinical Oncology 41, no. 4_suppl (2023): 572. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.572.

Full text
Abstract:
572 Background: ICP-192 (gunagratinib), developed by InnoCare Pharma, is a novel pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR 1, 2, 3 and 4 activities irreversibly by covalent binding. Here we present data from an ongoing phase IIa dose-expansion study (ICP-CL-00301 NCT03758664) of gunagratinib in patients with cholangiocarcinoma (CCA). Methods: Eligible participants were aged 18-75 years, had locally advanced or metastatic CCA with FGFR2 fusions or rearrangements, and had disease progression after ≥1 prior treatment or intolerant of prior
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Innocare"

1

Jabar, Alia. "Karaktärisering av spatial upplösning i röntgenmikroskopi." Thesis, Mittuniversitetet, Institutionen för elektronikkonstruktion, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:miun:diva-42387.

Full text
Abstract:
X-ray imaging was a very important detection that is used in many useful functionalities as in healthcare. It would be powerful and facilitate several functions if we could come up with a method that gives a better resolution when doing X-ray imaging. This will be done by using two different detectors, a commercial detector (Innocare) and a direct converting detector (Medipix3). These two detectors have different properties. In addition to these detectors, a radiation source that radiates with X-rays has been used and a line mask that provides the ability to read the resolution of the image. T
APA, Harvard, Vancouver, ISO, and other styles
2

Macleod, Kenneth Alexander. "Validation and application of a photo-acoustic gas analyser for multiple breath inert gas washout in children." Thesis, University of Edinburgh, 2014. http://hdl.handle.net/1842/33295.

Full text
Abstract:
Multiple breath washout (MBW) of inert gas for assessment of airway disease in children is an emerging technique. In many studies Lung Clearance Index (LCI), derived from multiple breath washout of SF6, is more able to detect early or mild lung disease than standard lung function measurements. It is also able to detect very early lung disease in progressive conditions such as Cystic Fibrosis (CF). Where infants born with this condition were thought to have minimal lung disease activity, LCI is higher in these children than healthy controls. Lack of available commercial devices has hampered exp
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Innocare"

1

Aidan Dixon, Software Engineering Manager at Advantech Innocore. Blurb, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Innocare"

1

Putz, Matthias. "Innovationsallianz „Green Carbody Technologies“ – InnoCaT®." In Ressourceneffizienz. Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-52889-1_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Minakov, Andrei Vladimirovich, and Liudmila Nikolaevna Ivanova. "THEORETICAL ASPECTS OF ASSESSING THE IMPACT OF INDUSTRIAL CLUSTERS ON THE SOCIO-ECONOMIC DEVELOPMENT OF THE REGION." In Economics and Law. Publishing house Sreda, 2023. http://dx.doi.org/10.31483/r-106055.

Full text
Abstract:
The creation of industrial clusters is becoming an increasingly popular tool of regional policy, and therefore there is a need to assess the impact of clusters on socio-economic development. Purpose of the study: to assess the impact of INNOKAM cluster on the socio-economic development of the Republic of Tatarstan. The study reveals that the contribution of industries, in which the cluster "INNOCAM" operates, in the total industrial production of the region has increased to 48.5%, cluster members form more than 25% of manufacturing production, also the cluster plays a signifi
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Innocare"

1

Grzesik, B., S. Gläsner, T. Walter, et al. "InnoCube: final design of the wireless satellite technology demonstration." In Small Satellites Systems and Services Symposium (4S 2024), edited by Max Petrozzi-Ilstad. SPIE, 2025. https://doi.org/10.1117/12.3062480.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Scroccaro, Alessandra, and Milena Bigatto. "INNOVATION SKILLS, COMPETENCE EVALUATION, AND SELF-DIRECTED LEARNING: THE CASE OF INNOCORE, A BIOTECH INTERNATIONAL PILOT CHALLENGE." In 17th International Technology, Education and Development Conference. IATED, 2023. http://dx.doi.org/10.21125/inted.2023.0586.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kuhn, M., A. Hornung, L. Sieverding, C. Schlensak, M. Hofbeck, and G. Wiegand. "Comparative Noninvasive Measurement of Cardiac Output Based on the Inert Gas Rebreathing Method (Innocor®) and MRI in Patients with Univentricular Hearts." In 50th Annual Meeting of the German Society for Pediatric Cardiology (DGPK). Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1628345.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Innocare' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography